Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates

Journal of Infection

Volumn 71, Issue 1, 2015, Pages 117-127

  Jones, Sophie ^a   Grignard, Lynn ^a   Nebie, Issa ^b   Chilongola, Jaffu ^c   Dodoo, Daniel ^d   Sauerwein, Robert ^e   Theisen, Michael ^f,g,h   Roeffen, Will ^e   Singh, Shrawan Kumar ⁱ   Singh, Rajesh Kumar ⁱ   Singh, Sanjay ⁱ   Kyei Baafour, Eric ^d   Tetteh, Kevin ^a   Drakeley, Chris ^a   Bousema, Teun ^a,e  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Burkina Faso   (Burkina Faso)

^c KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^d University of Ghana   (Ghana)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f STATENS SERUM INSTITUT   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h Rigshospitalet   (Denmark)

ⁱ Gennova Biopharmaceuticals Limited   (India)

Author keywords

Gamete; Gametocyte; Immunity; Plasmodium falciparum; Polymorphism; Transmission

Indexed keywords

MICROORGANISM PROTEIN; PROTEIN PFS230; PROTEIN PFS48 45; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PARASITE ANTIGEN; PFS230 ANTIGEN, PLASMODIUM FALCIPARUM; PFS48-45 PROTEIN, PLASMODIUM FALCIPARUM; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BURKINA FASO; CHILD; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG TARGETING; FEMALE; GAMETOCYTE; GENE SEQUENCE; GENETIC VARIABILITY; GHANA; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALARIA; MALE; MICROBIAL GENE; MOLECULAR RECOGNITION; NONHUMAN; PARASITE PREVALENCE; PFS48 45 GENE; PLASMODIUM FALCIPARUM; SINGLE NUCLEOTIDE POLYMORPHISM; TANZANIA; ANTIBODY PRODUCTION; BLOOD; CROSS-SECTIONAL STUDY; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; MALARIA FALCIPARUM;

ADOLESCENT; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; BURKINA FASO; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; GHANA; HUMANS; MALARIA, FALCIPARUM; MALE; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS; TANZANIA;

EID: 84930540661     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.03.007     Document Type: Article

References (49)

1. Barnes K.I., Chanda P., Ab Barnabas G. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar J 2009, 8(Suppl. 1):S8.
2. Ceesay S.J., Casals-Pascual C., Erskine J., Anya S.E., Duah N.O., Fulford A.J., et al. Changes in malaria indices between 1999 and 2007 in the Gambia: a retrospective analysis. Lancet 2008, 372(9649):1545-1554.
3. World Health Organization, G.S WHO: world malaria report 2012 2012.
4. Okell L.C., Griffin J.T., Kleinschmidt I., Hollingsworth T.D., Churcher T.S., White M.J., et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS One 2011, 6(5):e20179.
5. Griffin J.T., Hollingsworth T.D., Okell L.C., Churcher T.S., White M., Hinsley W., et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 2010, 7(8).
6. Targett G.A., Greenwood B.M. Malaria vaccines and their potential role in the elimination of malaria. Malar J 2008, 7(Suppl. 1):S10.
7. Sauerwein R.W. Malaria transmission-blocking vaccines: the bonus of effective malaria control. Microbes Infect 2007, 9(6):792-795.
8. Kaslow D.C. Transmission-blocking immunity against malaria and other vector-borne diseases. Curr Opin Immunol 1993, 5(4):557-565.
9. Vermeulen A.N., Ponnudurai T., Beckers P.J., Verhave J.P., Smits M.A., Meuwissen J.H. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J Exp Med 1985, 162(5):1460-1476.
10. Bousema T., Roeffen W., Meijerink H., Mwerinde H., Mwakalinga S., van Gemert G.J., et al. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS One 2010, 5(11):e14114.
11. Bousema J.T., Roeffen W., van der Kolk M., de Vlas S.J., van de Vegte-Bolmer M., Bangs M.J., et al. Rapid onset of transmission-reducing antibodies in javanese migrants exposed to malaria in Papua, Indonesia. Am J Trop Med Hyg 2006, 74(3):425-431.
12. Drakeley C.J., Bousema J.T., Akim N.I.J., Teelen K., Roeffen W., Lensen A.H., et al. Transmission reducing immunity is inversely related to age in P. falciparum gametocyte carriers. Parasite Immunol 2006, 28:185-190.
13. Conway D.J., Machado R.L., Singh B., Dessert P., Mikes Z.S., Povoa M.M., et al. Extreme geographical fixation of variation in the Plasmodium falciparum gamete surface protein gene Pfs48/45 compared with microsatellite loci. Mol Biochem Parasitol 2001, 115(2):145-156.
14. Miura K., Takashima E., Deng B., Tullo G., Diouf A., Moretz S.E., et al. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay. Infect Immun 2013, 81(12):4377-4382.
15. Brooker S., Kolaczinski J.H., Gitonga C.W., Noor A.M., Snow R.W. The use of schools for malaria surveillance and programme evaluation in Africa. Malar J 2009, 8:231.
16. Theisen M., Roeffen W., Singh S.K., Andersen G., Amoah L., van de Vegte-Bolmer M., et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 2014, 32(22):2623-2630.
17. Hermsen C.C., Verhage D.F., Telgt D.S., Teelen K., Bousema J.T., Roestenberg M., et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007, 25(15):2930-2940.
18. Farrance C.E., Rhee A., Jones R.M., Musiychuk K., Shamloul M., Sharma S., et al. A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum. Clin Vaccine Immunol 2011, 18(8):1351-1357.
19. Saeed M., Roeffen W., Alexander N., Drakeley C.J., Targett G.A., Sutherland C.J. Plasmodium falciparum antigens on the surface of the gametocyte-infected erythrocyte. PLoS ONE 2008, 3(5):e2280.
20. Proietti C., Verra F., Bretscher M.T., Stone W., Kanoi B.N., Balikagala B., et al. Influence of infection on malaria-specific antibody dynamics in a cohort exposed to intense malaria transmission in northern Uganda. Parasite Immunol 2013, 35(5-6):164-173.
21. Drakeley C.J., Corran P.H., Coleman P.G., Tongren J.E., McDonald S.L., Carneiro I., et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U.S.A 2005, 102(14):5108-5113.
22. Corran P.H., Cook J., Lynch C., Leendertse H., Manjurano A., Griffin J., et al. Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malar J 2008, 7:195.
23. Baidjoe A., Stone W., Ploemen I., Shagari S., Grignard L., Osoti V., et al. Combined DNA extraction and antibody elution from filter papers for the assessment of malaria transmission intensity in epidemiological studies. Malar J 2013, 12:272.
24. Anthony T.G., Polley S.D., Vogler A.P., Conway D.J. Evidence of non-neutral polymorphism in Plasmodium falciparum gamete surface protein genes Pfs47 and Pfs48/45. Mol Biochem Parasitol 2007, 156(2):117-123.
25. Liljander A., Wiklund L., Falk N., Kweku M., Martensson A., Felger I., et al. Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2). Malar J 2009, 8:78.
26. Schoepflin S., Valsangiacomo F., Lin E., Kiniboro B., Mueller I., Felger I. Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping. Malar J 2009, 8:250.
27. Plasmodium Genomics Resource PlasmoDB (plasmodb.org), [accessed 15.06.14].
28. Bousema T., Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011, 24(2):377-410.
29. Kaslow D.C. Transmission-blocking vaccines: uses and current status of development. Int J Parasitol 1997, 27(2):183-189.
30. Ouedraogo A.L., Roeffen W., Luty A.J., de Vlas S.J., Nebie I., Ilboudo-Sanogo E., et al. Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission. Infect Immun 2011, 79(12):4957-4964.
31. Bousema J.T., Drakeley C.J., Kihonda J., Hendriks J.C., Akim N.I., Roeffen W., et al. A longitudinal study of immune responses to Plasmodium falciparum sexual stage antigens in Tanzanian adults. Parasite Immunol 2007, 29(6):309-317.
32. Bousema J.T., Drakeley C.J., Sauerwein R.W. Sexual-stage antibody responses to P. falciparum in endemic populations. Curr Mol Med 2006, 6(2):223-229.
33. Roeffen W., Mulder B., Teelen K., Bolmer M., Eling W., Targett G.A., et al. Association between anti-Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon. Parasite Immunol 1996, 18(2):103-109.
34. Babiker H.A., Ranford-Cartwright L.C., Walliker D. Genetic structure and dynamics of Plasmodium falciparum infections in the Kilombero region of Tanzania. Trans R Soc Trop Med Hyg 1999, 93(Suppl. 1):11-14.
35. Arnot D. Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission. Trans R Soc Trop Med Hyg 1998, 92(6):580-585.
36. Agyeman-Budu A., Brown C., Adjei G., Adams M., Dosoo D., Dery D., et al. Trends in multiplicity of Plasmodium falciparuminfections among asymptomatic residents in the middle belt of Ghana. Malar J 2013, 12:22.
37. Meyrowitsch D.W., Pedersen E.M., Alifrangis M., Scheike T.H., Malecela M.N., Magesa S.M., et al. Is the current decline in malaria burden in sub-Saharan Africa due to a decrease in vector population?. Malar J 2011, 10:188.
38. Ishengoma D.S., Francis F., Mmbando B.P., Lusingu J.P., Magistrado P., Alifrangis M., et al. Accuracy of malaria rapid diagnostic tests in community studies and their impact on treatment of malaria in an area with declining malaria burden in north-eastern Tanzania. Malar J 2011, 10:176.
39. Bousema T., Kreuels B., Gosling R. Adjusting for heterogeneity of malaria transmission in longitudinal studies. J Infect Dis 2011, 204(1):1-3.
40. Bejon P., Warimwe G., Mackintosh C.L., Mackinnon M.J., Kinyanjui S.M., Musyoki J.N., et al. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 2009, 77(5):1917-1923.
41. Bousema J.T., Gouagna L.C., Drakeley C.J., Meutstege A.M., Oketch B.A., Akim I.N., et al. Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya. Malar J 2004, 3:18.
42. Drakeley C.J., Eling W., Teelen K., Bousema J.T., Sauerwein R., Greenwood B.M., et al. Parasite infectivity and immunity to Plasmodium falciparum gametocytes in Gambian children. Parasite Immunol 2004, 26:159-165.
43. Bouharoun-Tayoun H., Oeuvray C., Lunel F., Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995, 182(2):409-418.
44. Healer J., McGuinness D., Carter R., Riley E. Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230. Parasitology 1999, 119(Pt 5):425-433.
45. Graves P.M., Carter R., Burkot T.R., Quakyi I.A., Kumar N. Antibodies to Plasmodium falciparum gamete surface antigens in Papua New Guinea sera. Parasite Immunol 1988, 10(2):209-218.
46. Chowdhury D.R., Angov E., Kariuki T., Kumar N. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One 2009, 4(7):e6352.
47. Roeffen W., Beckers P.J., Teelen K., Lensen T., Sauerwein R.W., Meuwissen J.H., et al. Plasmodium falciparum: a comparison of the activity of Pfs230-specific antibodies in an assay of transmission-blocking immunity and specific competition ELISAs. Exp Parasitol 1995, 80(1):15-26.
48. Escalante A.A., Grebert H.M., Chaiyaroj S.C., Riggione F., Biswas S., Nahlen B.L., et al. Polymorphism in the gene encoding the Pfs48/45 antigen of Plasmodium falciparum. XI. Asembo Bay Cohort Project. Mol Biochem Parasitol 2002, 119(1):17-22.
49. Cooreman M.P., Leroux-Roels G., Paulij W.P. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001, 8(3):237-247.